Ignite Creation Date:
2024-05-06 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 12:45 PM
Study NCT ID:
NCT03522246
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-12
First Post:
2018-04-09
Brief Title:
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Sponsor:
pharmaand GmbH
Organization:
pharmaand GmbH
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Complete Response |
| Epithelial Ovarian Cancer |
| Primary Peritoneal |
| Fallopian Tube Cancer |
| Newly Diagnosed |
| FIGO Stage III-IV |
| Partial Response |
Keywords:
| Name | View |
|---|---|
| Primary Treatment | View |
| PARP inhibitor | View |
| PARPi | View |
| HRD | View |
| ATHENA | View |
| homologous recombination | View |
| DNA repair | View |
| LOH | View |
| DNA defect | View |
| DNA anomaly | View |
| Rucaparib | View |
| Nivolumab | View |
| PD-1 | View |
| Immuno- | View |
| oncology | View |
| Tumor | View |
| mutational | View |
| burden | View |
| BRCA | View |
| First-line | View |
| Primary Therapy | View |